No Data
No Data
Insider Sale: Chief Scientific Officer of $OCUL (OCUL) Sells 2,948 Shares
Ocular Therapeutix to Participate in December Investor and Scientific Conferences
Swelling Losses Haven't Held Back Gains for Ocular Therapeutix (NASDAQ:OCUL) Shareholders Since They're up 302% Over 1 Year
Scotiabank Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $22
Ocular Therapeutix (OCUL) Gets a Buy From Scotiabank
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $15